Tekla Life Sciences Investors (NYSE:HQL) Experiences Heavier than Usual Trading Volume


Tekla Life Sciences Investors shares had a trading volume of 239K by the end of trading on Tuesday. Overall, volume was up 175.95% over the stocks normal daily volume.

Investors are more bearish on shares of the company of late if you take a look at the increase in short interest. The firm experienced a rise in short interest of 74.88% as of October 13, 2017 from the last reporting period. Short interest increased from 55,451 to 96,971 over that timeframe. Days to cover increased 1.0 to 2.0 and the percentage of shorted shares is 0.00% as of October 13.

The following firms have recently changed their position in HQL. As of quarter end New England Private Wealth Advisors LLC had bought 89 shares growing its holdings by 0.7%. The value in dollars went from $255,000 to $264,000 increasing 3.5% for the reporting period. As of the end of the quarter Oppenheimer & Co Inc had acquired a total of 343 shares growing its stake by 1.3%. The value of the company’s investment in Tekla Life Sciences Investors increased from $548,000 to $572,000 a change of 4.4% quarter over quarter.

As of the end of the quarter Citigroup Inc had disposed of 2 shares trimming its position 0.1%. The value of the total investment in Tekla Life Sciences Investors increased from $38,000 to $39,000 a change of $1,000 since the last quarter. Raymond James & Associates trimmed its position by shedding 3,288 shares a decrease of 3.0% in the quarter. Raymond James & Associates owns 106,024 shares with a value of $2,277,000. The value of the position overall is down by 0.1%.

In the market the company is trading up since yesterday’s close of 18.81. The company’s P/E ratio is N/A and the market value is 399.27M. As of the last earnings report the EPS was $-5.96 with 21.17M shares currently outstanding.

H&Q Life Sciences Investors (the Fund) is a diversified, closed-end management investment company. The Fund’s investment objective is long-term capital appreciation through investment in life science companies (including biotechnology, pharmaceutical, diagnostics, managed healthcare and medical equipment, hospitals, healthcare information technology and services, devices and supplies) agriculture and environmental management. The Fund invests primarily in securities of public and private companies..